<DOC>
	<DOCNO>NCT00804648</DOCNO>
	<brief_summary>This study compare patient symptom anterior segment safety patient treat timolol hemihydrate , generic timolol gel form solution timolol maleate .</brief_summary>
	<brief_title>Patient Satisfaction With Timolol Subjects With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>willing comply investigator 's protocol 's instruction patient signature inform consent document primary openangle glaucoma , pigment dispersion exfoliation glaucoma , ocular hypertension least one eye screen intraocular pressure must consider safe , eye nonqualifying eye intraocular pressure able control safely pharmacologic therapy study medicine alone currently treat one glaucoma medication , untreated intraocular pressure less equal 28 mm Hg visit 2 eye abnormality prevent reliable applanation tonometry either eye opacity subject uncooperativeness restricts adequate examination ocular fundus anterior chamber either eye concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye history allergic hypersensitivity poor tolerance component preparation use trial female childbearing potential use reliable mean birth control pregnant lactating female clinically significant , serious , severe medical psychiatric condition participation ( current participation ) investigational drug device trial within 30 day prior Visit 1 severe prior visual acuity field loss cause inability understand trial procedure , thus inability give inform consent progressive retinal optic nerve disease apart glaucoma serious systemic ocular disease intraocular laser surgery within past three month corneal intraocular conventional surgery within past 6 month concurrent use systemic corticosteroid , IV , oral , dermal topical ophthalmic route . subject require tear replacement drop allergy medication sympathomimetics 24 hour prior schedule study visit contraindication betablocker usage include : reactive airway disease , uncontrolled heart failure , second well third degree cardiac block , myasthenia gravis subject investigator believe risk glaucomatous progression participation trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>